AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

Overview of attention for article published in Lancet Neurology, April 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 5 news outlets
blogs: 5 blogs
policy: 2 policy sources
twitter: 8 X users
patent: 11 patents

facebook: 3 Facebook pages
wikipedia: 23 Wikipedia pages
reddit: 1 Redditor
f1000: 2 research highlight platforms

Readers on

mendeley: 723 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 6 news stories from 5 outlets.

Gene therapy AAV-GAD wins RMAT designation for Parkinson’s

PARKINSON'S NEWS TODAY, 15 May 2025

The U.S. Food and Drug Administrated (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to AAV-GAD…

Gene Therapy AAV-GAD Gains Regenerative Medicine Advanced Therapy Designation as Potential Parkinson Treatment

Neurology Live, 12 May 2025

AAV-GAD gene therapy targets the subthalamic nucleus to restore brain circuit function in Parkinson's disease, showing…

The evolution of adeno-associated virus capsids for CNS gene therapy

BioInsights, 29 Oct 2019

CNS gene therapy: how we got to where we are now The first CNS-directed AAV gene therapy trials started in the early 2000s…

Two Catalysts For Axovant Sciences In March

Seeking Alpha, 11 Feb 2019

Summary AXON has confirmed initial data are coming from two trials in March. I take a look at AXO-Lenti-PD and previous data…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.